Table 1.
Results of quality control rounds 1 and 4
| Results of Quality Control Round 1 | |||||||||
| Cytospin Label | Lab 1 | Lab 2 | Lab 3 | Lab 4 | Lab 5 | Lab 6 | Lab 7 | Lab 8 | Lab 9 |
| QC1 A1 | NEa | 0 | 0 | 1 | NE | NE | 0 | ND | 0 |
| QC1 A2 | NE | 0 | 0 | 0 | NDb | NE | 0 | ND | 0 |
| QC1 A3 | NE | 0 | 0 | 0 | ND | NE | 0 | ND | 0 |
| QC1 A4 | 0 | 0 | 0 | 0 | ND | 1 | 0 | ND | 0 |
| QC1 B1 | 0 | 6 | 9 | 5 | >100c | 53 | 42 | ND | 10 |
| QC1 B2 | 0 | 0 | 0 | 0 | ND | 3 | 15 | ND | 0 |
| QC1 B3 | 0 | 0 | 0 | 4 | ND | 3 | 1 | ND | 0 |
| QC1 C1 | >100 | >100 | NE | >100 | >100 | >100 | >100 | ND | >100 |
| QC1 C2 | 50 | >100 | NE | >100 | >100 | >100 | >100 | ND | >100 |
| QC1 C3 | NE | 0 | 0 | 2 | 1 | 0 | 4 | ND | 0 |
| QC1 G1 | >100 | >100 | >100 | >100 | NE | >100 | >100 | ND | >100 |
| QC1 G2 | Cd | 1 | 2 | 0 | NE | 0 | 15 | ND | 0 |
| QC1 G3 | NE | 0 | 0 | 0 | NE | 0 | 18 | ND | 0 |
| QC1 G4 | 0 | 1 | 0 | 0 | NE | 0 | 21 | ND | 0 |
| QC1 I1 | >100 | >100 | NE | NE | >100 | NE | >100 | ND | ND |
| QC1 I2 | 1 | 1 | 0 | NE | 0 | NE | ND | ND | ND |
| QC1 I3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ND | 0 |
| QC1 I4 | 11 | C | 5 | 2 | 4 | 3 | 32 | ND | 7 |
| QC1 I5 | 0 | 0 | 0 | 0 | ND | 0 | 0 | ND | 0 |
| QC1 I6 | 40 | >100 | >100 | >100 | ND | >100 | >100 | ND | >100 |
| QC1 I7 | 0 | 2 | ND | 0 | ND | 0 | 0 | ND | 0 |
| QC1 I8 | 0 | 0 | ND | 2 | ND | 0 | 8 | ND | 0 |
| QC1 N1 | 0 | >100 | C | C | ND | 23 | 92 | ND | 80 |
| QC1 N2 | 0 | 0 | 0 | NE | ND | 0 | 4 | ND | 2 |
| QC1 N3 | 1 | 1 | 2 | 0 | ND | 7 | 14 | ND | 7 |
| QC1 S1 | 0 | ND | 0 | 2 | 1 | NE | 16 | ND | 0 |
| QC1 S2 | 0 | ND | 0 | 0 | 0 | NE | 18 | ND | 0 |
| QC1 S3 | 0 | ND | 0 | 0 | 0 | 0 | 0 | ND | ND |
| QC1 S4 | 0 | ND | 0 | 0 | 0 | 0 | 0 | ND | ND |
| QC1 S5 | 0 | 1 | 3 | 0 | ND | 1 | 22 | ND | 0 |
| QC1 S6 | C | 3 | 2 | 0 | ND | 0 | 27 | ND | 0 |
| Results of Quality Control Round 4 | |||||||||
| Cytospin Label | Lab 1 | Lab 2 | Lab 3 | Lab 4 | Lab 5 | Lab 6 | Lab 7 | Lab 8 | Lab 9 |
| QC4 A1 | 0 | 0 | NE | NE | 0 | 0 | 0 | 0 | 0 |
| QC4 A2 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 |
| QC4 B1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 B2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 C1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | ND | >100 |
| QC4 C2 | 0 | C | ND | ND | 0 | 0 | 1 | ND | 4 |
| QC4 F1 | 0 | 3 | 0 | 0 | 0 | 1 | 2 | 0 | 10 |
| QC4 F2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 G1 | 48 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| QC4 N1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 N2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 S1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QC4 S2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a
Not evaluable.
b
Not done.
c
More than 100 positive cells or more than 2 clusters.
d
One or two positive clusters.
Participants 1-8 used an immunocytological staining assay to evaluate the quality control samples. Participant 9 detected residual neuroblastoma cells using an automatic immunofluorescence plus FISH device (AIPF). The number of GD2-positive cells (quality control round 1) or the number of criteria-positive cells (quality control round 4) is reported.